LEVERAGING GENOMIC AND COMPUTATIONAL KNOWLEDGE TO DRIVE THE PERSONAL MEDICINE

Genegoggle is an innovative biotech company that offers platform-centric solutions to the challenges of precision medicine and contributes to realizing the future of health. 

JAKUB MIECZKOWSKI
Co-founder, and Research Lead, Genegoggle

Through its disruptive approach and computational tools for identification of next-generation drug targets, Genegoggle aims to develop selective delivery systems that target specific types of cells.

Based on the data provided by its Genegoggle Epigenetic Viewer software, Genegoggle is systematically analyzing the 3D structure of DNA, identifying epigenetic modifications and mutations, comparing healthy and pathological cells, measuring parameters between genomic regions of interest, and understanding the current state of the chromatin. This technology is a prelude to novel epigenetics-based applications such as identifying genome-editing targets, inspecting DNA damage for space traveling purposes, selective drug activation, and many others.

With a Ph.D. in molecular biology and a habilitation in medical science, Jakub Mieczkowski has a diverse background that combines epigenetics, computational analysis, and statistics expertise.

As a mathematician by training, he brings a unique perspective to the company. As a co-founder and research lead, Jakub leverages his computational and statistical knowledge to drive the development of innovative approaches for identifying novel drug targets.

Applying Multilayered Analysis Techniques